First PREMIER Bank’s Anika Therapeutics ANIK Stock Holding History

First PREMIER Bank’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-700	Closed	-$38K	–	234
2017 Q4	$38K	Hold	700	–	–	0.03%	153
2017 Q3	$41K	Hold	700	–	–	0.03%	141
2017 Q2	$35K	Hold	700	–	–	0.03%	138
2017 Q1	$30K	Hold	700	–	–	0.02%	144
2016 Q4	$34K	Hold	700	–	–	0.03%	133
2016 Q3	$33K	Hold	700	–	–	0.02%	151
2016 Q2	$38K	Hold	700	–	–	0.03%	110
2016 Q1	$31K	Hold	700	–	–	0.02%	112
2015 Q4	$27K	Buy	+700	New	+$26.8K	0.02%	115

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

First PREMIER Bank's ANIK Position: Q1 2018 in Review

First PREMIER Bank sold out of Anika Therapeutics (ANIK) in Q1 2018, closing a stake of 700 shares — an estimated $38K sold.

First PREMIER Bank first reported a position in ANIK in Q4 2015 and held it in 9 quarters. The position peaked at $41K in Q3 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q1 2018.

First PREMIER Bank reported no remaining Anika Therapeutics position as of Q1 2018 after selling out during the quarter.
First PREMIER Bank sold 700 Anika Therapeutics shares in Q1 2018, an estimated $38K.
First PREMIER Bank first reported a position in Anika Therapeutics in Q4 2015 and held it in 9 quarters.
First PREMIER Bank's Anika Therapeutics position peaked at $41K in Q3 2017.
170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2018.

Based on First PREMIER Bank's 13F filing for Q1 2018, filed 9 Apr 2018.